Recital 13, Regulation (EU) 2025/2086

In forcesince 17 Oct 2025

To identify individual experts with relevant in-depth specialised expertise, the HTA secretariat should be able to consult the stakeholder network established pursuant to Article 29 of Regulation (EU) 2021/2282, the European reference networks for rare and complex diseases and other relevant sources, agencies, and organisations. In order to ensure the highest scientific quality of the joint clinical assessment, in making the final selection, the JCA Subgroup should give priority to individual experts who have expertise, across several Member States, in the medical condition to be treated, therapeutic area, the type of health technology that is the subject of the joint clinical assessment or other specific expertise. These experts should be consulted during the joint clinical assessment.